Findings from randomized controlled trials that studied the effect of the drug Anakinra, which is a recombinant of the naturally occurring IL-1RA and binds to IL-1 receptors, also reported conflicting results with some finding IL-1RA to improve β-cell function [54], whereas others reporting no difference in insulin sensitivity after Anakinra treatment in obese non-T2D individuals [55]. This evidence concerns the gene INS and type 2 diabetes mellitus.